000078786 001__ 78786
000078786 005__ 20240104111809.0
000078786 0247_ $$2doi$$a10.1016/j.vetimm.2018.04.004
000078786 0248_ $$2sideral$$a105933
000078786 037__ $$aART-2018-105933
000078786 041__ $$aeng
000078786 100__ $$0(orcid)0000-0001-9818-508X$$aBarrachina, L.$$uUniversidad de Zaragoza
000078786 245__ $$aDifferentiation of equine bone marrow derived mesenchymal stem cells increases the expression of immunogenic genes
000078786 260__ $$c2018
000078786 5060_ $$aAccess copy available to the general public$$fUnrestricted
000078786 5203_ $$aMesenchymal stem cells (MSCs) are a promising treatment for equine musculoskeletal injuries because of their ability to regulate the inflammation and to differentiate into other cell types. Since interest in allogeneic therapy is rising, concerns about MSC immunogenicity need to be addressed. Differentiated MSCs from several species increase their expression of immunogenic molecules and induce alloresponses, but equine MSC immunogenic profile after differentiation has not been reported. Therefore, the aim of this study was to assess the gene expression of immunogenic markers in tri-lineage differentiated equine bone marrow derived MSCs (eBM-MSCs). For this purpose, eBM-MSCs (n = 4) were differentiated into osteoblasts, adipocytes and chondrocytes. Differentiation was confirmed by specific staining and gene expression of lineage-related markers. Subsequently, gene expression of MHC-I, MHC-II, CD40 and CD80 was analyzed in undifferentiated (control) and tri-lineage differentiated eBM-MSCs. Osteogenesis and adipogenesis, but not chondrogenesis, significantly upregulated MHC-I; MHC-II expression significantly increased in the three lineages, while CD40 and CD80 expression did not change. Despite this, MHC-I and MHC-II upregulation after differentiation might lead to increased immunogenicity and risk of allorecognition, either eBM-MSCs differentiate in vivo after administration or they are differentiated prior to administration, with potential negative consequences for effectiveness and safety of allogeneic therapy.
000078786 536__ $$9info:eu-repo/grantAgreement/ES/DGA/LAGENBIO-GROUP$$9info:eu-repo/grantAgreement/ES/MINECO/AGL2011-28609
000078786 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000078786 590__ $$a1.846$$b2018
000078786 591__ $$aVETERINARY SCIENCES$$b28 / 141 = 0.199$$c2018$$dQ1$$eT1
000078786 591__ $$aIMMUNOLOGY$$b130 / 157 = 0.828$$c2018$$dQ4$$eT3
000078786 592__ $$a0.749$$b2018
000078786 593__ $$aVeterinary (miscellaneous)$$c2018$$dQ1
000078786 593__ $$aImmunology$$c2018$$dQ1
000078786 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000078786 700__ $$0(orcid)0000-0002-1075-8267$$aRemacha, A.R.$$uUniversidad de Zaragoza
000078786 700__ $$0(orcid)0000-0001-7188-0461$$aRomero, A.$$uUniversidad de Zaragoza
000078786 700__ $$0(orcid)0000-0001-5740-0185$$aZaragoza, P.$$uUniversidad de Zaragoza
000078786 700__ $$0(orcid)0000-0002-8712-2275$$aVázquez, F.J.$$uUniversidad de Zaragoza
000078786 700__ $$0(orcid)0000-0003-3289-2675$$aRodellar, C.$$uUniversidad de Zaragoza
000078786 7102_ $$11001$$2420$$aUniversidad de Zaragoza$$bDpto. Anatom.,Embri.Genét.Ani.$$cÁrea Genética
000078786 7102_ $$11009$$2617$$aUniversidad de Zaragoza$$bDpto. Patología Animal$$cÁrea Medicina y Cirugía Animal
000078786 773__ $$g200 (2018), 1-6$$pVet. immunol. immunopathol.$$tVETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY$$x0165-2427
000078786 8564_ $$s311073$$uhttps://zaguan.unizar.es/record/78786/files/texto_completo.pdf$$yPostprint
000078786 8564_ $$s50855$$uhttps://zaguan.unizar.es/record/78786/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000078786 909CO $$ooai:zaguan.unizar.es:78786$$particulos$$pdriver
000078786 951__ $$a2024-01-04-11:01:33
000078786 980__ $$aARTICLE